Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study of BET and MEK Inhibition in Advanced Uveal Melanoma

NCT05677373 is registered in ClinicalTrials.gov with Alliance for Clinical Trials in Oncology as lead sponsor.

NCT NCT05677373
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05677373 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study of BET and MEK Inhibition in Advanced Uveal Melanoma
Lead sponsor
Alliance for Clinical Trials in Oncology
Phase
Phase 1/2
Overall status
Withdrawn
Start date
January 13, 2023
Completion date
July 31, 2025
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

advanced uveal melanoma, metastatic uveal melanoma, unresectable uveal melanoma